Logo
x

Search

Subscribe Now

EGFR-Mutated NSCLC

Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC

Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC

  • May 20, 2021
Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

  • February 4, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.